Overview

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and

Status:
RECRUITING
Trial end date:
2030-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.
Phase:
PHASE3
Details
Lead Sponsor:
UCB Biopharma SRL
Treatments:
bimekizumab